Cart
sales@molnova.com
3-O-Acetyl-20-Hydroxyecdysone
CAS No. 22961-68-8
3-O-Acetyl-20-Hydroxyecdysone( —— )
Catalog No. M21779 CAS No. 22961-68-8
3-O-Acetyl-20-Hydroxyecdysone is an steroid isolated from the roots of Cyanotis arachnoidea C.B.Clark.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 401 | Get Quote |
|
| 5MG | 319 | Get Quote |
|
| 10MG | 472 | Get Quote |
|
| 25MG | 753 | Get Quote |
|
| 50MG | 1051 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name3-O-Acetyl-20-Hydroxyecdysone
-
NoteResearch use only, not for human use.
-
Brief Description3-O-Acetyl-20-Hydroxyecdysone is an steroid isolated from the roots of Cyanotis arachnoidea C.B.Clark.
-
Description3-O-Acetyl-20-Hydroxyecdysone is an steroid isolated from the roots of Cyanotis arachnoidea C.B.Clark.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number22961-68-8
-
Formula Weight522.67
-
Molecular FormulaC??H??O?
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)(O)CC[C@@H](O)[C@](C)(O)[C@H]1CCC2(O)C3=CC([C@@]4([H])C[C@H](OC(C)=O)[C@H](O)C[C@]4(C)[C@@]3([H])CC[C@]12C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Dlin-MeOH
Dlin-MeOH is a lipid membrane and a potential nucleic acid carrier for the synthesis of DLin-MC3-DMA.
-
3-Hydroxy-4-methoxya...
3'-Hydroxy-4'-methoxyacetophenone is an active P. spinosa extract. It possesses anti-inflammatory activity and prevented injuries due to administration of acetic acid in the colon.
-
MAGE-A3 195-203
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.
